Clicky

Brii Bioscience Ltd(BRIBF)

Description: Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. It develops product candidates for the treatment of chronic hepatitis B infection, human immunodeficiency virus, MDR/XDR Gram, MDR TB mycobacteria, and Covid-19 diseases; and postpartum depression and major depressive disorder diseases. The company was incorporated in 2017 and is based in Beijing, China.


Keywords: Disease Health Sciences Infection Tuberculosis Chronic Hepatitis B Infection Antibiotic Resistant Bacteria Infectious And Central Nervous System Diseases Postpartum Depression Treatment Of Infectious And Central Nervous System Diseases

Home Page: www.briibio.com

Building 7
Beijing, 100192
China
Phone:


Officers

Name Title
Dr. Zhi Hong Ph.D. Co-founder, Exec. Chairman & CEO
Dr. Ankang Li C.F.A., J.D., Ph.D. Chief Financial & Strategy Officer, Company Sec. and Exec. Director
Dr. Eleanor de Groot Ph.D. Chief Technology Officer
Ms. Karen Del Barrio Neuendorff Chief People Officer & Head of HR
Mr. Coy Stout Head of Patient Advocacy
Dr. Li Yan M.D., Ph.D. Chief Medical Officer
Dr. Lianhong Xu Ph.D. Head of Discovery
Dr. Qing Zhu Ph.D. Head of China R&D
Dr. David Margolis M.D., M.P.H. VP & Head of Infectious Diseases Therapy Area
Dr. Susannah Cantrell Ph.D. Chief Bus. Officer

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.9537
Price-to-Sales TTM: 10.6422
IPO Date:
Fiscal Year End: December
Full Time Employees: 123
Back to stocks